Chengdu Xinrui Taikang Technology

Chengdu Xinrui Taikang Technology is a Chinese biotechnology company specializing in the development of innovative chemical drugs and medical solutions. Based in Chengdu, the company operates as a subsidiary of Yunnan Xinrui Yucheng Biopharmaceutical and focuses on therapeutic areas such as neurology, metabolic disorders, and emergency medicine. Its lead product, Xintailin (Sodium Bicarbonate Ringer's Injection), is a next-generation electrolyte solution currently in the regulatory approval stage for treating metabolic acidosis and fluid loss. The company's research pipeline also features small molecule candidates for hemorrhagic stroke, insomnia, and Alzheimer's disease. Chengdu Xinrui Taikang leverages expertise in computational pharmacy and molecular dynamics to advance its drug discovery efforts. The company has been recognized as a National High-tech Enterprise for its contributions to pharmaceutical innovation.